These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36449140)

  • 1. Translational Approach for Predicting Human Pharmacokinetics of Engineered Therapeutic Monoclonal Antibodies with Increased FcRn-Binding Mutations.
    Haraya K; Tachibana T
    BioDrugs; 2023 Jan; 37(1):99-108. PubMed ID: 36449140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative prediction of therapeutic antibody pharmacokinetics after intravenous and subcutaneous injection in human.
    Haraya K; Tachibana T; Nezu J
    Drug Metab Pharmacokinet; 2017 Aug; 32(4):208-217. PubMed ID: 28734646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting pharmacokinetic profile of therapeutic antibodies after iv injection from only the data after sc injection in cynomolgus monkey.
    Haraya K; Tachibana T; Nezu J
    Xenobiotica; 2017 Mar; 47(3):194-201. PubMed ID: 27151820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction.
    Dong JQ; Salinger DH; Endres CJ; Gibbs JP; Hsu CP; Stouch BJ; Hurh E; Gibbs MA
    Clin Pharmacokinet; 2011 Feb; 50(2):131-42. PubMed ID: 21241072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach.
    Betts A; Keunecke A; van Steeg TJ; van der Graaf PH; Avery LB; Jones H; Berkhout J
    MAbs; 2018 Jul; 10(5):751-764. PubMed ID: 29634430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of novel Fc-engineered monoclonal and multispecific antibodies in cynomolgus monkeys and humanized FcRn transgenic mouse models.
    Valente D; Mauriac C; Schmidt T; Focken I; Beninga J; Mackness B; Qiu H; Vicat P; Kandira A; Radošević K; Rao S; Darbyshire J; Kabiri M
    MAbs; 2020; 12(1):1829337. PubMed ID: 33079615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simple Approach to Accurately Predict Pharmacokinetics of Therapeutic Monoclonal Antibodies after Subcutaneous Injection in Humans.
    Haraya K; Tachibana T
    Clin Pharmacokinet; 2021 Jan; 60(1):111-120. PubMed ID: 32779124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimation of Clearance and Bioavailability of Therapeutic Monoclonal Antibodies from Only Subcutaneous Injection Data in Humans Based on Comprehensive Analysis of Clinical Data.
    Haraya K; Tachibana T
    Clin Pharmacokinet; 2021 Oct; 60(10):1325-1334. PubMed ID: 33954956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review of allometric scaling exponents for IgG mAbs.
    Rowland SP; Nixon E; Mohan K; Wang Q; Yates JWT
    Xenobiotica; 2024 Sep; 54(9):609-614. PubMed ID: 39067010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modification of the Fc Region of a Human Anti-oncostatin M Monoclonal Antibody for Higher Affinity to FcRn Receptor and Extension of Half-life in Cynomolgus Monkeys.
    Nnane IP; Han C; Jiao Q; Tam SH; Davis HM; Xu Z
    Basic Clin Pharmacol Toxicol; 2017 Jul; 121(1):13-21. PubMed ID: 28132416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Various Approaches to Translate Non-Linear Pharmacokinetics of Monoclonal Antibodies from Cynomolgus Monkey to Human.
    Singh R; Moreno M; Stanimirovic D
    Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):555-567. PubMed ID: 34120326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned?
    Deng R; Iyer S; Theil FP; Mortensen DL; Fielder PJ; Prabhu S
    MAbs; 2011; 3(1):61-6. PubMed ID: 20962582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Quantitative Prediction Method for the Human Pharmacokinetics of Fc-Fusion Proteins.
    Yokoyama M; Suzuki E; Oitate M; Watanabe N
    Eur J Drug Metab Pharmacokinet; 2023 Sep; 48(5):541-552. PubMed ID: 37530974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of improved FcRn binding on the subcutaneous bioavailability of monoclonal antibodies in cynomolgus monkeys.
    Datta-Mannan A; Witcher DR; Lu J; Wroblewski VJ
    MAbs; 2012; 4(2):267-73. PubMed ID: 22377715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Fc variant with two mutations confers prolonged serum half-life and enhanced effector functions on IgG antibodies.
    Ko S; Park S; Sohn MH; Jo M; Ko BJ; Na JH; Yoo H; Jeong AL; Ha K; Woo JR; Lim C; Shin JH; Lee D; Choi SY; Jung ST
    Exp Mol Med; 2022 Nov; 54(11):1850-1861. PubMed ID: 36319752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies.
    Avery LB; Wang M; Kavosi MS; Joyce A; Kurz JC; Fan YY; Dowty ME; Zhang M; Zhang Y; Cheng A; Hua F; Jones HM; Neubert H; Polzer RJ; O'Hara DM
    MAbs; 2016; 8(6):1064-78. PubMed ID: 27232760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys.
    Deng R; Loyet KM; Lien S; Iyer S; DeForge LE; Theil FP; Lowman HB; Fielder PJ; Prabhu S
    Drug Metab Dispos; 2010 Apr; 38(4):600-5. PubMed ID: 20071453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisited.
    Wang W; Prueksaritanont T
    Biopharm Drug Dispos; 2010 May; 31(4):253-63. PubMed ID: 20437464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys.
    Datta-Mannan A; Chow CK; Dickinson C; Driver D; Lu J; Witcher DR; Wroblewski VJ
    Drug Metab Dispos; 2012 Aug; 40(8):1545-55. PubMed ID: 22584253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Translate Pharmacokinetics of PD-1/PD-L1 Monoclonal Antibodies from Cynomolgus Monkey to Human: Comparison of Different Approaches.
    Chen W; Wang L; Ruan Z; Lou H; Jiang B
    J Pharm Sci; 2024 Sep; 113(9):2915-2921. PubMed ID: 38986869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.